A detailed history of Jane Street Group, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 294,860 shares of ITCI stock, worth $25.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
294,860
Previous 481,205 38.72%
Holding current value
$25.5 Million
Previous $33 Million 34.58%
% of portfolio
0.0%
Previous 0.04%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $12.7 Million - $15.1 Million
-186,345 Reduced 38.72%
294,860 $21.6 Million
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $27.8 Million - $34.2 Million
428,607 Added 814.87%
481,205 $33 Million
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $7.36 Million - $8.65 Million
-114,318 Reduced 68.49%
52,598 $3.64 Million
Q4 2023

Feb 14, 2024

BUY
$46.37 - $73.65 $6.86 Million - $10.9 Million
148,015 Added 783.11%
166,916 $12 Million
Q3 2023

Nov 14, 2023

SELL
$52.09 - $64.1 $7.28 Million - $8.96 Million
-139,850 Reduced 88.09%
18,901 $984,000
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $2.79 Million - $3.4 Million
51,112 Added 47.48%
158,751 $10.1 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $1.53 Million - $1.99 Million
34,913 Added 48.01%
107,639 $5.83 Million
Q4 2022

Feb 14, 2023

SELL
$44.07 - $54.45 $958,698 - $1.18 Million
-21,754 Reduced 23.02%
72,726 $3.85 Million
Q3 2022

Nov 14, 2022

BUY
$42.7 - $59.99 $2.89 Million - $4.06 Million
67,729 Added 253.18%
94,480 $4.4 Million
Q2 2022

Aug 16, 2022

SELL
$43.0 - $65.64 $232,157 - $354,390
-5,399 Reduced 16.79%
26,751 $1.53 Million
Q1 2022

May 17, 2022

SELL
$38.74 - $62.09 $322,123 - $516,278
-8,315 Reduced 20.55%
32,150 $1.97 Million
Q4 2021

Feb 15, 2022

BUY
$35.2 - $53.42 $835,366 - $1.27 Million
23,732 Added 141.83%
40,465 $2.12 Million
Q3 2021

Nov 16, 2021

BUY
$28.72 - $42.49 $320,974 - $474,868
11,176 Added 201.12%
16,733 $624,000
Q2 2021

Aug 16, 2021

SELL
$29.3 - $44.5 $188,486 - $286,268
-6,433 Reduced 53.65%
5,557 $227,000
Q1 2021

May 18, 2021

SELL
$30.8 - $39.51 $2.11 Million - $2.71 Million
-68,563 Reduced 85.12%
11,990 $407,000
Q4 2020

Feb 17, 2021

BUY
$23.34 - $32.22 $268,316 - $370,401
11,496 Added 16.65%
80,553 $2.56 Million
Q3 2020

Nov 17, 2020

SELL
$17.61 - $31.86 $2.8 Million - $5.07 Million
-159,174 Reduced 69.74%
69,057 $1.77 Million
Q2 2020

Aug 17, 2020

BUY
$14.35 - $26.64 $3.05 Million - $5.67 Million
212,720 Added 1371.41%
228,231 $5.86 Million
Q1 2020

May 15, 2020

SELL
$12.31 - $33.12 $3,865 - $10,399
-314 Reduced 1.98%
15,511 $239,000
Q4 2019

Feb 14, 2020

BUY
$7.26 - $38.49 $114,889 - $609,104
15,825 New
15,825 $543,000
Q4 2017

Feb 15, 2018

SELL
$14.27 - $16.79 $567,660 - $667,906
-39,780 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$10.77 - $22.1 $428,430 - $879,138
39,780
39,780 $628,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.16B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.